Lipoprotein(a) consists of a low-density lipoprotein containing apolipoprotein (apo) B-100 and of the genetically polymorphic apo(a). It is not known where and how lipoprotein(a) is assembled and whether there exists a precursor for lipoprotein(a). We have determined the phenotype, concentration, and distribution of apo(a) in plasma from patients with lipoprotein lipase (LPL) deficiency (type I hyperlipoproteinemia, n = 14), in apo E 2 /2 homozygotes with type III hyperlipoproteinemia (n = 12) and in controls (n = 16). In the two genetic conditions, there is grossly impaired catabolic conversion of apo B-100-containing precursor lipoproteins to low-density lipoproteins. Considering apo(a) type, the plasma concentration of apo(a) was normal in type III patients but significantly reduced in LPL deficiency. Despite the defects in the catabolism of other apo B-containing lipoproteins, the distribution of apo(a) was only moderately affected in both metabolic disorders, with 66.7% (type I) and 74.7% (type III) being present as the characteristic lipoprotein(a) in the density range of 1.05-1.125 g/ml (controls 81.6%). The remainder was distributed between the triglyceride-rich lipoproteins (type I 12.4%, type III 8.5%, controls 4.7%) and the lipid-poor bottom fraction (type I 19.3%, type III 15.3%, controls 12.6%). In all conditions most apo(a) (57-88%) dissociated from the triglyceriderich lipoproteins upon recentrifugation and was recovered as lipoprotein(a). These data suggest that lipoprotein(a) is not generated from a triglyceride-rich precursor. Lipoprotein(a) may be secreted directly into plasma or may be formed by preferential binding of secreted apo(a) to existing low-density lipoprotein. (J. Clin. Invest. 1992. 90:1958-1965 
mature myocardial infarction and cerebrovascular disease (2) . Lp(a) is composed of a low-density lipoprotein (LDL)-like particle carrying all the lipids ofthat complex and ofthe Lp(a) specific glycoprotein termed apolipoprotein (a) [apo(a)]. Plasma apo(a) is almost entirely synthesized by the liver (3) . Apo(a) has been sequenced on the protein and cDNA level and is highly homologous to plasminogen (4, 5) . In particular it contains a kringle 4 motifthat is repeated several times in the apo(a) gene and protein. Apo(a) exhibits a genetic size polymorphism with individual isoforms ranging in apparent Mr from -400 to > 800 kD (6) . Originally six genetic apo(a) isoforms, designated LpF, LpB, LpS 1, LpS2, LpS3, and LpS4, which are determined by alleles at the apo(a) structural gene locus ( 1, 7), were described. The existence of more than 20 different isoforms, which are caused by genetic variation in the number of kringle 4 repeats in the apo(a) gene (9, 10), has recently been reported (8) . The genetic isoforms are associated with plasma Lp(a) levels in Caucasian, Asian, and African populations ( 1, 11 ) and are a significant predictor of coronary heart disease risk ( 12) . The LDL moiety of Lp(a) is similar to authentic LDL in chemical composition and contains apo B-100 ( 1, 2) .
LDL are the catabolic end products in plasma of triglyceride-rich very low-density lipoproteins (VLDL). In normolipidemic healthy subjects VLDL are secreted from liver parenchymal cells into plasma and are converted to intermediate-density lipoproteins (IDL) at the endothelia of capillaries through hydrolysis of core triglycerides by lipoprotein lipase with transfer of surface components to high-density lipoprotein (HDL) ( 13) . IDL are further degraded to LDL in a process that is believed to require the action of hepatic triglyceride lipase ( 14, 15) and apo E ( 16) . Different mutations affect the catabolism of apo B-containing precursor lipoproteins. Autosomal recessive lipoprotein lipase (LPL) deficiency results in the accumulation in plasma of the triglyceride-rich chylomicrons and VLDL and in a low LDL concentration (equaling type I hyperlipoproteinemia). Mutations in the apo E gene that affect binding of apo E to the LDL receptor and also affect lipolysis cause accumulation of chylomicron remnants and IDL in plasma owing to impaired cellular uptake and a defect in the interconversion of these lipoproteins to LDL (type III hyperlipoproteinemia) ( 17) . These genetic conditions are valuable natural models that allow one to study the question of whether or not Lp(a) is formed in a process that is analogous to the formation ofLDL, and whether or not this process requires the same machinery. We have determined the phenotype, concentration, and distribution of apo(a) in the plasma lipoproteins and lipoprotein-free fractions from patients with these genetic defects in the interconversion of triglyceride-rich lipoproteins to LDL. The results demonstrate that both genetic defects only moderately affect the distribution of apo(a) in plasma. This is in sharp contrast to the distribution of apo B-100 that is markedly affected by mutations in the LPL-and apo E genes.
Methods

Subjects
Control EDTA plasma was obtained from 16 healthy volunteers of known apo(a) phenotype with Lp(a) concentrations of2.9-115 mg/dl covering the normal range. All were Caucasians living in Innsbruck, Austria. Mean cholesterol levels were 222±35 mg/dl and mean triglycerides were 136±50 mg/dl. EDTA plasma was obtained from 14 patients with familial LPL deficiency at the Division of Metabolism ofthe Department of Medicine of the University of Washington in Seattle. These patients had postheparin LPL activity below the 99% confidence interval of 34 normal Caucasians. They were on a very low fat diet and were receiving no medications. Mean LPL activity in the 14 patients was 9.9±7.5 nmol FFA/min ml plasma (controls 220±59) (18) . Their hepatic triglyceride lipase activity was within the normal range (females 101±24 nmol FFA/min ml plasma, males 154±46 nmol FFA/min *ml plasma (19) . Plasma 
Methods
Apo(a) quantification. Apo(a) was quantified in human serum, or in fractions from density gradient ultracentrifugation by a sandwich ELISA essentially as described (20) . In brief, affinity-purified polyclonal anti-human Lp(a) antibody (5 ,g/ml) was bound to the wells of a microtiter plate. The blocking buffer used was 0.1% casein in PBS (pH 7.3). 1O-Ml or 50-id sera or fractions were added in appropriate dilutions (ranging from 1/ 10 to 1/2,000). The apo(a) antigen was detected with the anti-(a) monoclonal antibody 1A2 (20) (21) and Fless et al. (22) as outlined (20) . The assay has a sensitivity of2 ng of Lp(a).
Apo(a) phenotyping. Ap(a) phenotypes were determined by immunoblotting exactly as described (23) this study was initiated, improved separation techniques have enabled us to distinguish more than 10 apo(a) isoforms by SDS-PAGE (11, 24) and more than 20 isoforms were separated by SDS-agarose-gel electrophoresis (8) . Because better separation of isoforms does not affect the linear relationship between apo(a) isoform size and Lp(a) concentration, no higher resolution of isoforms was required for this study. We therefore used the same methodology and the same apo(a) standards as in previous studies. Isoforms that did not comigrate exactly with one of the isoform standards were binned with the closest respective isoform in the standard (25) .
Ultracentrifugation. Density gradient ultracentrifugation ofhuman plasma was done according to Redgrave et al. (26), with minor modifications. Three KBr-density solutions of 3 ml each (d = 1.006, 1.019, 1.063 g/ml) were layered sequentially into the tubes of an SW41.Ti rotor (Beckman Instruments, Inc., Fullerton, CA). Finally, 4 ml plasma of d = 1.21 g/ml (adjusted with solid KBr) were applied at the bottom. Centrifugation was then performed in a SW.41-Ti rotor at 40,000 rpm at 10°C for 24 or 48 h. After centrifugation, 0.5-ml fractions were collected from below using a fractionating system (Beckman Instruments, Inc.) and a fraction collector (LKB Produker, Bromma, Sweden). Since lipoproteins are not in equilibrium after this 24-h density gradient ultracentrifugation, two control samples with a high percentage ofapo(a) in the triglyceride-rich and the bottom fractions were run comparatively for 24 and 48 h (Tables I and II) . As expected this resulted in a slight difference (-0.002 g/ml) in Lp(a) peak density (data not shown). The distribution of apo(a) between fractions was however not changed (Table II) . Moreover, five controls that were centrifuged for 48 h had a distribution of apo(a) that was not significantly different from the distribution in 11 controls run for 24 h and the total group of controls (Table II) . Therefore, all other density gradients were centrifuged for 24 h. The apo(a) distribution in gradients was evaluated by ELISA (see above) and in selected gradients by densitometric scanning of immunoblots using a (Hirschmann Geratebau, Unterhaching, FRG) densitometer. Apo E phenotyping. Apolipoprotein E phenotyping was performed by isoelectric focusing of delipidated VLDL exactly as described (27) .
Lipid and LPL activity measurements. Cholesterol and triglycerides were determined by commercially available test kits (Boehringer Mannheim GmbH, Mannheim, FRG). LPL activity in plasma (after 60 U heparin/kg body weight) was measured with triolein-phosphatidylcholine emulsion (28) . The LPL activity was that precipitated from whole plasma by the 5D2 monoclonal antibody, the remaining activity was hepatic lipase activity.
Statistical procedures. The distribution of apo(a) between groups was compared by the nonparametric Kruskal-Wallis test (29) . Pairwise comparisons were done by the Wilcoxon test (29) .
Results
Concentration ofLp(a) in the plasma from patients with LPL deficiency and with type III hyperlipoproteinemia. The concentrations of Lp(a) in plasma from 14 patients with LPL deficiency were very low when compared to controls (Tables III   Table III Table  IV ). Overall the low Lp(a) concentrations in the S2 phenotype and the high frequency of "null" types resulted in the low Lp(a) concentration in the total group of LPL-deficient patients. The low concentration of Lp(a) in patients with LPL deficiency might be the consequence of random differences in allele frequencies between patients and controls or of an effect of the LPL-deficiency gene on Lp(a) levels. There was an overrepresentation of "null" phenotypes in the LPL-deficient patients. Although the number of LPL-deficient subjects is small and we do not know their apo(a) DNA phenotypes, it seems unlikely that the observed difference is a consequence of random differences in allele frequencies between patients and controls. The high frequency of "null" types more likely is a consequence of the effect ofthe defective LPL alleles on Lp(a) levels rather than a true overrepresentation of this type in the sample. An Lp(a) lowering effect of the LPL gene would explain both the low concentrations of Lp(a) in S2 patients and the overrepresentation of the "null" phenotype. The concentration of apo(a) was further determined in 12 untreated, unrelated apo E2 homozygotes with type III hyperlipoproteinemia. Upon SDS-PAGE the apo E protein of all patients had the characteristic mobility of the apo E2 (arg 158__ cys) mutation (30) . All patients had excessive accumulation of remnants and IDL in plasma and exhibited the density gradient profiles characteristic for this disorder (Fig. 1) . Lp(a) plasma concentrations in the patients were not significantly different from those of controls of identical apo(a) phenotype (Table IV) .
Distribution ofapo(a) in the plasmafrom normolipidemic subjects. Plasma from 16 healthy normolipidemic individuals was subjected to density gradient ultracentrifugation. The dis- (Fig. 1) . Because Lp(a) levels were too low in nine of the type I patients the plasma' distribution of apo(a) could be determined in only five ofthem. The overall distribution ofapo(a) in the density gradient was significantly different among the three groups (Tables I and II) . Comparisons between all three groups ofthe amount ofapo(a) in the triglyceride-rich, the LDL/IDL, the Lp(a), and the bottom fractions demonstrated significant differences for each single fraction (Kruskal-Wallis test P < 0.05 for each fraction). Pairwise comparisons ofapo(a) in fractions from type I, type III, and control groups showed that both type I and type III subjects differed significantly from controls (Wilcoxon test P < 0.05 for each fraction) but not among each other. The differences were characterized by a higher relative mean concentration ofapo(a) in the triglyceride-rich and IDL fractions and in the bottom fractions from patients with type I and type III hyperlipoproteinemia and a slightly lower concentration ofapo(a) in Lp(a) (Tables I and II). It is noteworthy that the higher concentration of apo(a) in triglyceride-rich lipoproteins was paralleled by a higher concentration of apo(a) in the bottom of the gradient. The differences between patients and controls, though statistically significant were, however, only moderate and there was wide overlap between the groups. There were subjects in the control group that had > 10% ofapo(a) in the triglyceride-rich lipoproteins (Tables I and II) which is above the mean in type I and type III patients. As in the controls the majority (66.7%) of apo(a) was present as Lp(a) in the LPL-deficient patients. On the average, < 10% was associated with the triglyceride-rich lipoproteins which are the major lipoprotein class in this condition (see Fig. 1 and Table I ), while 19.3% ofapo(a) was found in the bottom fraction from type I patients. Likewise each single type III patient had at least 68% of apo(a) in the Lp(a) fractions. Only 2.7-17.6% were present in the less dense fractions. There was no accumulation of apo(a) paralleling the accumulation of cholesterol in IDL or the triglyceride-rich/ remnant-rich top fractions of the gradients (Fig. 1) .
Apolipoprotein(a) in triglyceride-rich lipoproteins. In all subjects investigated, including normotriglyceridemic controls there was apo(a) immunoreactivity in the triglyceride-rich fractions. The relative concentrations varied considerably among subjects ranging from < 1% to > 16% (Table I) . Even within the same subject apo(a) concentrations in the triglyceride-rich lipoproteins varied severalfold at different times (data not shown). Immunoblotting experiments demonstrated that the apo (a)-reactive material in this fraction has the same apparent molecular mass as apo(a) in the plasma ofthe same subject and hence represents the same genetic isoform(s) (Figs. 2 and  3 ). This suggests that this material is authentic apo(a) and not any cross-reacting material. In apo(a) heterozygotes both isoforms were present in the triglyceride-rich lipoproteins (Fig.  3) , but the higher Mr band was frequently more intense or even exclusively present in the triglyceride-rich fraction as compared to the Lp(a) lipoprotein from the same subject (Fig. 3 ).
This preferential association ofthe high M, isoform with triglyceride-rich lipoproteins was seen in type III and control subjects ( Fig. 3 and data not shown) . In the context of this study it was important to clarify the nature of the apo(a) associated with the triglyceride-rich lipoproteins. To this end triglyceride-rich lipoprotein fractions from the density gradients were subjected to recentrifugation under identical conditions. The outcome of two such experiments, one in a control and one in a type III subject is shown in Figs. 4 and 5. Upon recentrifugation, 57-88% of apo(a) dissociated from TG-rich lipoproteins and the majority was recovered as Lp(a) lipoprotein in the typical density range (Figs. 4 and 5 ).
Discussion
The occurrence of apo(a) in triglyceride-rich lipoproteins and the significance ofthis finding has remained controversial. The first report on the occurrence of apo(a) immunoreactivity in VLDL was published by Rittner and Goenechea in 1969 (31) . Later apo(a) protein was demonstrated in triglyceride-rich postprandial "chylomicrons" (32) . Since then several in vivo and in vitro studies have suggested an association of Lp(a)/ apo(a) with triglyceride-rich lipoproteins (33-36). Bersot et al. (32) have speculated that apo(a) might be of intestinal origin. However, studies on patients undergoing liver transplantation clearly demonstrated that most (> 95%) of apo(a) in plasma and hence of Lp(a) is derived from this organ and not from the intestine or other sources (3). The transplantation data did however not answer the questions whether Lp(a) is assembled in the liver or in the plasma compartment and whether Lp(a) has a triglyceride-rich precursor or not. The present study was undertaken to address the latter question. Conditions that impair the conversion of triglyceride-rich lipoproteins to LDL are expected also to impair the interconversion ofa putative triglyceride-rich Lp(a) precursor to Lp(a), if such a precursor exists and ifthe same machinery for interconversion is used. Therefore we have analyzed apo(a) in two genetic conditions that grossly impair the intravascular catabolism of triglyceride-rich lipoproteins and their remnants to LDL, namely LPL-deficiency and type III hyperlipoproteinemia.
The fairly normal distribution of apo(a) in the plasma from patients with LPL deficiency and type III hyperlipoproteinemia observed here is in sharp contrast to the grossly impaired distribution of cholesterol and apo B which reflect the defects in lipoprotein catabolism in these pathological conditions. As in the normolipidemic controls most apo (a) was present in the Lp(a) lipoprotein complex in the plasma from both patient groups (Fig. 1) . Apo(a) may be hidden or present in a different conformation in non-Lp(a) fractions (triglyceriderich lipoproteins, > 1.21 g/ml bottom fraction) and apo(a) might be detected differently in the triglyceride-rich lipoproteins from type I and type III patients by our apo(a) ELISA assay. Therefore the apo(a) distribution was also evaluated in selected density gradients by SDS-PAGE followed by densitometric scanning of the blots. A very good correlation between the two methods was obtained (r = 0.96, data not shown). This excellent agreement between the results from immunoblotting and the quantification by the ELISA is also demonstrated in Fig. 5 . Fig. 5 B, moreover, demonstrates that apo(a) in triglyceride-rich particles and in Lp(a) is recognized identically by the antibody. Hence apo(a) accumulates neither with the chylomicrons or VLDL when LPL is deficient nor with chylomicron remnants or IDL when apo E is defective. This suggests that metabolic steps that are essential for the generation of LDL in plasma do not operate for Lp(a). LDL is extremely low in patients with LPL deficiency and most apo B is associated with chylomicrons and VLDL in this genetic disorder (37) . Likewise LDL concentrations are usually low in patients with type III hyperlipoproteinemia and apo B is mainly associated with remnants and IDL. This is believed to reflect a defect in the interconversion of IDL to LDL in the absence of functional apo E ( 16) . The absence of any gross effect on Lp(a) oftwo different genetic defects in the pathway that results in LDL formation suggests that Lp(a) is not a product ofthe same metabolic cascade. Lp(a) may either be secreted from the liver as an intact native particle or parenchymal liver cells secrete apo(a) that then is preferentially assembled with LDL. Krempler et al. (38) have shown that radioiodinated apo B from VLDL, that itself did not contain apo(a), is not a precursor ofapo B in Lp(a). Together with the results presented here this suggests a direct synthesis of Lp(a) that bypasses the catabolic cascade ofthe other apo B-containing lipoproteins. This interpretation is consistent with results in Hep G2 cells that were transfected with recombinant apo(a) containing 17 kringle 4-like domains. These cells secreted recombinant apo(a) which was found complexed with apo B in the medium and floated with the density of Lp(a) (39) .
The distribution of apo(a) in the plasma from type I and type III patients was, however, not exactly identical with that in controls. Indeed the percentage of apo(a) associated with the triglyceride-rich and IDL fractions from LPL-deficient and type III patients was measured two-to three-fold higher than in the controls. This might be taken as an indication for a triglyceride-rich precursor of Lp(a). However, in terms of absolute amounts of apo(a) this slight increase was only moderate and might be explained by the affinity ofLp(a) particles to triglyceride-rich lipoproteins that has been demonstrated in vitro (33) (34) (35) (36) . In apo(a) heterozygotes the two apo(a) isoforms are in two distinct Lp(a) particles which have slightly different densities (40) . Our data suggest that there is a preferential association of Lp(a) particles containing high M, isoforms with the triglyceride-rich lipoproteins (Fig. 3 and data not shown) . The preferential association of higher M, isoforms of apo(a) with the triglyceride-rich lipoproteins seen here in fasting subjects was also observed by Bersot et al. (32) (43) .
The percentage of apo(a) found in the "bottom" fractions from LPL-deficient patients was also about twice as high as in controls. The reason for this is unclear as is the nature, origin, and relation to Lp(a) of apo(a) in the lipid-poor fractions. In patients with autosomal recessive abetalipoproteinemia apo(a) is almost exclusively present in this fraction as a lipidpoorcomplex with apo B-100 (20) . An apo(a)-apo B complex has also been demonstrated in the lipoprotein-free fractions of supernatant from Hep G2 cells that were transiently transfected with recombinant apo(a) (39) . Previous investigators have reported a range of 1.8-27.2% of apo(a) to occur in the lipoprotein-free bottom (21, (44) (45) (46) . The reason for these discrepant results are not clear but may relate to small numbers of subjects analyzed and/or technical problems, e.g., differential detection of apo(a) isoforms in various fractions by the antibodies used. In our sample the amount of apo(a) in the "bottom" ranged from < 1% to > 29% with a mean in controls of 12%. This covers the range reported in the previous studies. Our immunoblotting experiments not only confirmed the quantitative data from the ELISA but moreover demonstrate that the immunoreactive material in this fraction is authentic apo(a) having the same apparent M, as the respective genetic isoform(s) in plasma or Lp(a). This suggests that the apo(a) immunoreactivity detected in the lipoprotein-free fractions of the gradient by our ELISA is not a proteolytic cleavage product of apo(a).
The very low levels of Lp(a) in patients with LPL deficiency are remarkable. They parallel the low concentration of LDL in this pathological condition. The patients with LPL deficiency were from different ethnic groups (two Black, one Arab, one Vietnamese, nine Caucasian). Therefore apo(a) type specific Lp(a) levels are given only for the Caucasian patients in Table IV . However, the plasma Lp(a) concentrations ofthe three subjects ofBlack and Indian origin were also low in comparison to their respective reference populations which have much higher Lp(a) concentrations than Caucasians. ( 11 ) . No reference data are yet available for the Arab and Vietnamese patients. Individuals with Lp(a) concentrations < 2 mg/dl occur with a frequency ofless than one in five in Caucasian populations. Thus the chance that nine independent subjects all have Lp(a) concentrations < 2 mg/dl is -2 x 10-6. The low Lp(a) in LPL deficiency might reflect an increased removal capacity for Lp(a) either because LDL is low alone, or due to an increased LDL receptor activity. This effect of the LPL-gene on Lp(a) levels might be a further example for an interaction of two genes determining Lp(a) levels as has been previously demonstrated for the apo(a) and LDL receptor gene loci (23) , and for abetalipoproteinemia (20) .
